2 Role of RAG1 and RAG2 in B-cell development | 51 203. Mathijs A. Sanders, Anikó Szabó, Carla Exalto, Remco Hoogenboezem, Annelieke Zeilemaker, Jasper E. Koenders, Peter van Geel, Anita Schelen, H. Berna Beverloo, Jan J. Cornelissen, Anita W. Rijneveld, P. J. M. V. Extensive RAG-Mediated Rearrangements and Mutations in BCR-ABL1 and BCR-ABL1like Adult Acute Lymphoblastic Leukemia. Blood 128, 4067 (2016). 204. G, W. The infective theory of acute leukaemia. Br J Child Dis 10–20 (1917). 205. Ma, X. et al. Vaccination history and risk of childhood leukaemia. Int. J. Epidemiol. 34, 1100–1109 (2005). 206. Auvinen, A., Hakulinen, T. & Groves, F. Haemophilus influenzae type B vaccination and risk of childhood leukaemia in a vaccine trial in Finland. Br. J. Cancer 83, 956–958 (2000). 207. Mahowald, G. K., Baron, J. M. & Sleckman, B. P. Collateral damage from antigen receptor gene diversification. Cell 135, 1009–1012 (2008). 208. Tsai, A. G. et al. Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity. Cell 135, 1130–1142 (2008). 209. Place, A. E. et al. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. Pediatr. Blood Cancer 65, e27062 (2018). 210. Ratti, S. et al. B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? Cancers (Basel). 12, (2020). 211. Adam, E. et al. The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. Cancers (Basel). 9, (2017). 212. Ferrari, A. et al. Venetoclax durable response in adult relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia with JAK/STAT pathway alterations. Front. cell Dev. Biol. 11, 1165308 (2023). 213. Kołodrubiec, J. et al. Efficacy of ruxolitinib in acute lymphoblastic leukemia: A systematic review. Leuk. Res. 121, 106925 (2022). 214. Lee, S. et al. Ruxolitinib significantly enhances in vitro apoptosis in Hodgkin lymphoma and primary mediastinal B-cell lymphoma and survival in a lymphoma xenograft murine model. Oncotarget 9, 9776–9788 (2018). 215. Deak, D. et al. Let’s Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia. Front. Immunol. 10, 2856 (2019). 216. Ren, A. et al. CAR T-Cell Immunotherapy Treating T-ALL: Challenges and Opportunities. Vaccines 11, (2023). 217. Rao, D. S. et al. MicroRNA-34a perturbs B lymphocyte development by repressing the forkhead box transcription factor Foxp1. Immunity 33, 48–59 (2010). 218. de Oliveira, J. C. et al. Differential miRNA expression in childhood acute lymphoblastic leukemia and association with clinical and biological features. Leuk. Res. 36, 293–298 (2012).
RkJQdWJsaXNoZXIy MTk4NDMw